References
1. Solorzano GE, Phillips LH, 2nd. Inclusion body myositis: diagnosis, pathogenesis, and treatment options. Rheum Dis Clin North Am. 2011;37(2):173-83, v.
2. AlJohani NI, Carette S, Lipton JH. Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report. J Med Case Rep. 2015;9:214.
3. Naddaf E, Shelly S, Mandrekar J, Chamberlain AM, Hoffman EM, Ernste FC, et al. Survival and associated comorbidities in inclusion body myositis. Rheumatology (Oxford). 2021.
4. Greenberg SA. Inclusion body myositis: clinical features and pathogenesis. Nat Rev Rheumatol. 2019;15(5):257-72.
5. Naddaf E, Barohn RJ, Dimachkie MM. Inclusion Body Myositis: Update on Pathogenesis and Treatment. Neurotherapeutics. 2018;15(4):995-1005.
6. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009;10(5):470-81.